menu
    • menu
    [{"orgOrder":0,"company":"Immuto Scientific","sponsor":"DYDX","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Financing","leadProduct":"IMTO 4842","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Immuto Scientific","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Immuto Scientific \/ DYDX","highestDevelopmentStatusID":"4","companyTruncated":"Immuto Scientific \/ DYDX"},{"orgOrder":0,"company":"Immuto Scientific","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Immuto Scientific","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immuto Scientific \/ Daiichi Sankyo","highestDevelopmentStatusID":"2","companyTruncated":"Immuto Scientific \/ Daiichi Sankyo"}]

    Find Clinical Drug Pipeline Developments & Deals by Immuto Scientific

    Menu

    Immuto Scientific

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Immuto Scientific

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Immuto Scientific

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IMTO 4842

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : DYDX

                            Deal Size : $8.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Immuto Scientific Announces $8M Seed 2 Financing

                            Details : Backed by the financing, the company will advance its internal oncology pipeline, including IMTO 4842 toward IND-enabling studies for Acute Myeloid Leukemia.

                            Product Name : IMTO 4842

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            September 18, 2025

                            Lead Product(s) : IMTO 4842

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : DYDX

                            Deal Size : $8.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Immuto Scientific

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Immuto Scientific

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Daiichi Sankyo

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Immuto Scientific and Daiichi Sankyo Announces Collaboration

                            Details : Immuto will work with Daiichi Sankyo to discover new targets in solid tumors using its proprietary structural surfaceomics platform and to develop antibodies against these targets.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            September 18, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Daiichi Sankyo

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth